European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the company’s lead product candidate against influenza and COVID-19 Atriva’s ATR-002 molecule is the only host-cell targeting antiviral therapeutic specifically developed to treat severe respiratory infections caused by RNA (ribonucleic acid) viruses – it may prevent progression to critical-stage COVID-19 in hospitalised patients and holds strong potential in the current pandemic 
 The EIB venture debt transaction is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the EU research and innovation programme for 2014-2020 The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. Atriva’s ATR-002, an oral small molecule, has been proven to block the viral propagation of SARS-CoV-2 in pre-clinical trials, making it a much-needed therapeutic option for patients with moderate to severe COVID-19 symptoms who require hospitalisation. “While one needs to be careful when comparing COVID-19 to the flu, it might be helpful that both diseases have overlaps in their mechanisms of infection,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and transactions in Germany. “If, as Atriva’s research indicates, one small molecule can work to treat both diseases, this would be excellent news not only for the millions of people who fall ill from the flu every year but also for the many more who are affected by the coronavirus lately. An effective treatment would also lift a huge burden from our health systems and help mitigate the impact these diseases have on our daily lives and the economy. This is a case where EIB financing can contribute to addressing an extremely high unmet medical need, which is something I am proud of.” Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The European Union is doing all in its power to protect Europeans against coronavirus. The European Commission is coordinating the Coronavirus Global Response, the global action for universal access to tests, treatments and vaccines against coronavirus and for the global recovery. With this loan to Atriva, the EU continues its support for the development of innovative Covid-19 treatments. Their therapy can add to the range of complementary solutions that we need to tackle this disease.” Dr Rainer Lichtenberger, co-founder and CEO of Atriva, said: “The EIB clearly understands the need for an effective antiviral therapy against influenza and COVID-19 and the potential such a treatment holds to help patients around the world. We are grateful for the EIB’s support in advancing the clinical development of ATR-002 as an innovative host-targeting therapy against these prevalent and potentially devastating diseases. With the funding from the EIB, we can now take the next development steps –starting a Phase II study in patients with moderate to severe COVID-19 infections, followed by further clinical development work in influenza.” He continued: “When the coronavirus pandemic hit us all earlier this year, we saw that Atriva’s technology had the potential to play an important role in the fight against COVID-19, and we are excited to move forward in this work now. Our ultimate goal, though, is to develop a broad-spectrum antiviral drug that will also be effective against future viral outbreaks.” ATR-002 has been developed specifically to treat respiratory viral infections by inhibiting MEK, a host cell factor required for the replication of various RNA viruses, including the influenza virus and SARS-CoV-2. Atriva’s pre-clinical studies, performed at the Universities of Tübingen and Münster, have demonstrated that MEK inhibition by ATR-002 also prevents SARS-CoV-2 replication. In addition to its antiviral efficacy, ATR-002 shows a second beneficial effect: the MEK-inhibitor was able to significantly decrease pro-inflammatory cytokine and chemokine expression in cells. Cytokines and chemokines are proteins that coordinate the immune response throughout the body. In patients with COVID- 19, ATR-002 could prevent a cytokine storm and the associated disease progression to a life-threatening condition. This dual benefit, antiviral activity and immunomodulation, positions ATR-002 as a promising therapeutic candidate. Atriva has filed the respective patents with the European Patent Office. In addition, ATR-002 successfully completed a Phase I clinical trial in 2019 where it demonstrated excellent safety and tolerability in healthy volunteers. Atriva will receive the EIB loan in three tranches upon the completion of pre-defined milestones. The funds will support the company’s R&D for ATR-002, including clinical trial expenses, the technical transfer and manufacturing ramp-up needed to reach a commercial scale, as well as regulatory, intellectual property, pharmacovigilance and market access activities. Atriva will now start a multinational, double-blind, randomised clinical Phase II study in hospitalised patients with moderate to severe COVID-19 infections. The loan is backed by the Infectious Diseases Finance Facility (IDFF) set up as part of the EU’s Horizon 2020 programme. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through this facility, the EIB has supported European companies with total lending of around €400 million for developing cures, vaccines and diagnostics for various infectious diseases, most prominently the coronavirus. Background information  The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.
The InnovFin Infectious Diseases Finance Facility (IDFF) is dedicated to supporting the fight against infectious diseases. This joint European Commission and EIB Group initiative is part of Horizon 2020, the 2014-2020 EU research and innovation programme. The IDFF enables the EIB to provide between €7.5m and €75m of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combating infectious diseases. The financing mainly goes to projects that have completed the pre-clinical stage and need clinical approval for further development. The IDFF has been increased by €400 million to boost its capacity for tackling the outbreak of the coronavirus. The total EU contribution to the IDFF via Horizon 2020 is estimated at almost €700 million. About Atriva Therapeutics GmbH  Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent, which inhibits viral replication in influenza and favourably modulates the body’s immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects (NCT04385420). The Company has initiated a Phase II study to evaluate efficacy in hospitalised COVID- 19 patients while a Phase II study in influenza is planned to start in early 2021. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

Britisches Investorenkonsortium Franklin Road Ltd. erhöht Anteil an APEIRON Biologics signifikant auf über 13 % Hauptversammlung wählt Edward Charles MA, Geschäftsführer von Franklin Road Ltd., als neues Aufsichtsratsmitglied Wien, Österreich, 15. Oktober 2020: Die APEIRON Biologics AG gab im Rahmen ihrer außerordentlichen Hauptversammlung eine wesentliche Stärkung der Aktionärsstruktur sowie ein neues Aufsichtsratsmitglied bekannt. Demnach hat das britische Investorenkonsortium Franklin Road Limited seine Beteiligung an APEIRON Biologics signifikant erhöht. Franklin Road hatte sich bereits im Zuge der Kapitalerhöhung im Juni 2020 am Unternehmen beteiligt, konnte damals allerdings wegen der Überzeichnung der Kapitalerhöhung nicht den angestrebten Unternehmensanteil erwerben. Im Rahmen eines Secondary Offerings hat Franklin Road Aktien von bestehenden Aktionären erworben und so seinen Anteil am Unternehmen von knapp 1 % auf 13,06 % erhöht. Aufgrund der gestiegenen Beteiligung von Franklin Road an dem Unternehmen wurde auf der gestrigen Hauptversammlung Edward Charles, MA, Geschäftsführer von Franklin Road, als neues Aufsichtsratsmitglied der APEIRON Biologics AG gewählt. Vor allem die Kontakte und das weitreichende Netzwerk des neuen Ankerinvestors stellen ein wichtiges Fundament für die weitere strategische Entwicklung der APEIRON Biologics dar. „Das Engagement von Franklin Road bei APEIRON Biologics stärkt unsere Aktionärsstruktur und hat zugleich langjährigen und treuen Aktionären die erfolgreiche Realisierung ihres Investments in unserem Unternehmen ermöglicht“, sagte Peter Llewellyn-Davies, Vorstandsvorsitzender der APEIRON Biologics AG. „Seit Juni 2020 flossen rund 40 Millionen Euro Investoren- und Fördergelder in Finanzierungsrunden der APEIRON Biologics. Eine vor kurzem erschienene Fallstudie in der renommierten Fachzeitschrift The Lancet Respiratory Medicine[1]zeigt erstmals ermutigende Daten zur Behandlung eines COVID-19 Patienten mit APN01. Ich bedanke mich bei allen Beteiligten für diese hervorragenden Leistungen.“ Edward Charles MA, Geschäftsführer von Franklin Road Ltd., kommentierte: „Wir freuen uns sehr, die Entwicklungspipeline von APEIRON Biologics unterstützen zu können. Die Medikamentenkandidaten haben das Potenzial, die Überlebenschancen und Lebensqualität von Patienten signifikant zu verbessern, sowohl bei der Behandlung von COVID-19 als auch in der Immunonkologie. Wir sind hier, um das APEIRON-Team bei der Herausforderung zu unterstützen, diese einzigartigen und dringend benötigten Therapien so schnell und sicher zur Marktreife zu bringen wie möglich. Wir freuen uns auf die Ergebnisse der laufenden klinischen Phase II-Studie mit der COVID-19 Therapie APN01 in den nächsten Monaten.“ Dr. Manfred Reichl, Aufsichtsratsvorsitzender der APEIRON Biologics AG freut sich: „Die Stärkung und Internationalisierung unserer Aktionärsbasis und unseres Aufsichtsrats schaffen einen soliden Rahmen für die Arbeit an unseren laufenden klinischen Studien zu COVID-19 und in der Immunonkologie. Wir begrüßen Ed herzlich als Vertreter des neuen Ankerinvestors und Aufsichtsrats und freuen uns, dass APEIRON Biologics von seinem Engagement, seiner langjährigen Business-Erfahrung und seinen hervorragenden Kontakten profitieren kann.“ Über Franklin Road Limited Franklin Road Limited ist ein Investorenkonsortium bestehend aus britischen und europäischen Privatinvestoren und Familienstiftungen. Über APEIRON Biologics AG APEIRON Biologics AG ist ein europäisches privates Biotechnologieunternehmen mit Sitz in Wien, Österreich, das sich auf die Entdeckung, Entwicklung und Kommerzialisierung innovativer Immuntherapien gegen Krebs und Atemwegserkrankungen spezialisiert hat. APEIRONs APN01 / alunacedase alfa (rhsACE2) befindet sich in einer Phase-II-Studie zur Behandlung von COVID-19. APEIRON Biologics hat ein zugelassenes Produkt auf dem Markt, Qarziba®, zur Behandlung von pädiatrischen Neuroblastom-Patienten, das von EUSA Pharma weltweit vertrieben wird. Ein weiteres klinisches Programm des Unternehmens, APN401, ist eine „first-in-class“ autologe Zelltherapie zur Stärkung der Immunreaktivität über die Inhibierung des intrazellulären Master-Immune-Checkpoints Cbl-b. Die Produkte und Technologien von APEIRON Biologics basieren auf einem starken Patentportfolio und Partnerschaften mit führenden Pharmaunternehmen und akademischen Institutionen. Weitere Informationen unter www.apeiron-biologics.com. Für weitere Informationen wenden Sie sich bitte an: APEIRON Biologics AG Peter Llewellyn-Davies, CEO E-Mail: investors@apeiron-biologics.com www.apeiron-biologics.com Media and Investor Relations MC Services AG Julia Hofmann T +49 89 210 228 0 E-Mail: apeiron@mc-services.eu ZUKUNFTSBEZOGENE AUSSAGEN Diese Pressemitteilung enthält bestimmte vorausschauende Angaben, die Risiken und Unsicherheiten beinhalten. Diese Aussagen geben die Meinung von APEIRON zum Zeitpunkt dieser Pressemitteilung wieder. Derartige zukunftsbezogene Aussagen sind weder Versprechen noch Garantien, sondern hängen von vielen Risiken und Unwägbarkeiten ab, von denen sich viele der Kontrolle des Managements von APEIRON entziehen. Dies könnte dazu führen, dass die tatsächlichen Ergebnisse erheblich von den Prognosen in diesen zukunftsbezogenen Aussagen abweichen. Wir übernehmen ausdrücklich keine Verpflichtung, vorausschauende Aussagen hinsichtlich geänderter Erwartungen der Parteien oder hinsichtlich neuer Ereignisse, Bedingungen oder Umstände, auf denen diese Aussagen beruhen, öffentlich zu aktualisieren oder zu revidieren. [1] Zoufaly A. et al., The Lancet Respiratory Medicine, 2020, S2213-2600(20)30418-5 DOI: https://doi.org/10.1016/S2213-2600(20)30418-5

SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. Brian Johnson, Antlia Bioscience’s CEO commented, “chronic heart failure is a significantly unaddressed medical condition and a major public health concern. XL-protein’s PASylation® technology will allow us to safely and effectively translate our peptide into a meaningful therapeutic option for patients with chronic heart failure. “PASylation® is an excellent biological solution for plasma-half extension of therapeutic peptides, and we believe that PASylation® offers a simpler manufacturing process and superior pharmacological properties,” commented Claus Schalper, CEO of XL-protein. “We are excited to work with Antlia Bioscience to further exploit the potential of our technology and to develop new therapeutic options for the treatment of chronic heart failure.” Financial terms of the agreement have not been disclosed. About PASylation® Technology ‘PASylation’ involves the genetic fusion or chemical conjugation of a therapeutic protein or pharmaceutically active compound with a conformationally disordered polypeptide of defined sequence comprising the small natural amino acids Pro, Ala, and/or Ser. Due to the biophysical size effect, the typically rapid clearance via renal filtration of the original drug can be retarded by a factor 10-100, depending on the length of the PAS chain. PAS sequences are highly soluble while lacking charges, they are biochemically inert, non-toxic and non-immunogenic, they offer efficient recombinant protein production in a variety of biotechnological host organisms, and they show high stability in blood plasma but are biodegradable by intracellular proteases. About XL-protein GmbH XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels. For more information, please visit: www.xl-protein.com About Antlia Bioscience, Inc. Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and metabolic diseases. Using PASylation® and other state-of-the-art techniques, we turn promising peptides into groundbreaking therapies. We are driven to make a profound difference in the treatment of cardiovascular and metabolic diseases and believe that our efforts will result in a paradigm shift in how cardiovascular and metabolic diseases will be treated in the future. For more information, please visit: antliabio.com